Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Testori

Showing results (71-80 of 80) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 80 results.
British Journal of Cancer|March 13, 2014
Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in ItalyV Chiarion-Sileni, J Pigozzo, P A Ascierto, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 30, 2017
Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 studyP B Chapman, C Robert, J Larkin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 10, 2016
Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT)P Saiag, R Gutzmer, P A Ascierto, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|June 9, 2016
The interval between primary melanoma excision and sentinel node biopsy is not associated with survival in sentinel node positive patients - An EORTC Melanoma Group studyC M C Oude Ophuis, C Verhoef, P Rutkowski, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 23, 2017
Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trialJ Guo, R D Carvajal, R Dummer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 25, 2014
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II studyA M Di Giacomo, P A Ascierto, P Queirolo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 28, 2015
A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanomaE M Hersh, M Del Vecchio, M P Brown, et al.
ESMO Open|November 16, 2016
Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation studyR Gutzmer, L Rivoltini, E Levchenko, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 9, 2020
ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines CommitteeO Michielin, A van Akkooi, P Lorigan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 9, 2020
ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines CommitteeU Keilholz, P A Ascierto, R Dummer, et al.
Pageof 8

Showing results (71-80 of 80) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 80 results.
British Journal of Cancer|March 13, 2014
Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in ItalyV Chiarion-Sileni, J Pigozzo, P A Ascierto, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 30, 2017
Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 studyP B Chapman, C Robert, J Larkin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 10, 2016
Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT)P Saiag, R Gutzmer, P A Ascierto, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|June 9, 2016
The interval between primary melanoma excision and sentinel node biopsy is not associated with survival in sentinel node positive patients - An EORTC Melanoma Group studyC M C Oude Ophuis, C Verhoef, P Rutkowski, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 23, 2017
Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trialJ Guo, R D Carvajal, R Dummer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 25, 2014
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II studyA M Di Giacomo, P A Ascierto, P Queirolo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 28, 2015
A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanomaE M Hersh, M Del Vecchio, M P Brown, et al.
ESMO Open|November 16, 2016
Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation studyR Gutzmer, L Rivoltini, E Levchenko, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 9, 2020
ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines CommitteeO Michielin, A van Akkooi, P Lorigan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 9, 2020
ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines CommitteeU Keilholz, P A Ascierto, R Dummer, et al.
Pageof 8